Introduction

The narrative review by Anne K. Schlag, Jacob Aday, Iram Salam, Jo C. Neill, and David J. Nutt critically examines the evidence surrounding the potential harms associated with classic psychedelics. This review aims to differentiate between the risks that have been exaggerated or misconstrued in public and political discourse and those that are supported by scientific research.

Psychological and Psychiatric Risks

The authors systematically address concerns about abuse liability, dependence, and adverse psychological effects associated with psychedelic use. Their investigation reveals that medical risks are generally minimal, and many negative perceptions are not supported by current scientific evidence. The review emphasizes the importance of setting and conditions in influencing the safety and efficacy of psychedelics.

Medical Risks

The review dispels myths about the toxicity and overdose potential of psychedelics, highlighting the relatively low risk profile associated with their use. It calls for maintaining high safety and ethical standards in clinical and therapeutic settings where psychedelics are administered to ensure their safe integration into medical and psychological treatment paradigms.

Implications for Harm Reduction and Public Safety

The review suggests that the risks associated with psychedelic use can be effectively managed through informed, controlled, and supervised use. It supports ongoing research into the therapeutic applications of psychedelics and emphasizes the need for accurate information dissemination to promote their safe integration into mental health treatment.

Conclusion

Schlag and colleagues advocate for a nuanced understanding of psychedelics that acknowledges their therapeutic potential under appropriate conditions. By demystifying these substances and promoting their safe use, the review contributes to a growing consensus on the promise of psychedelics in addressing mental health challenges.